Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

11.14USD
19 Jul 2019
Change (% chg)

$-0.09 (-0.80%)
Prev Close
$11.23
Open
$11.21
Day's High
$11.45
Day's Low
$11.05
Volume
254,973
Avg. Vol
172,296
52-wk High
$11.85
52-wk Low
$5.76

Latest Key Developments (Source: Significant Developments)

Cytokinetics Inc Files For Mixed Shelf Of Up To $200 Million
Thursday, 9 May 2019 

May 9 (Reuters) - Cytokinetics Inc ::CYTOKINETICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Cytokinetics Reports Q1 Loss Per Share $0.54
Thursday, 9 May 2019 

May 9 (Reuters) - Cytokinetics Inc ::CYTOKINETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.Q1 REVENUE $8.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.9 MILLION.PHASE 1 DATA FOR CK-274 EXPECTED IN Q3 2019; PLANNING UNDERWAY FOR POTENTIAL PROGRESSION TO PHASE 2.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $176.6 MILLION AT MARCH 31, 2019.  Full Article

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Amgen Inc ::AMGEN, CYTOKINETICS AND SERVIER ANNOUNCE CONTINUATION OF GALACTIC-HF FOLLOWING PLANNED INTERIM ANALYSIS.AMGEN - DATA MONITORING COMMITTEE RECOMMENDS PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH HEART FAILURE TO CONTINUE WITHOUT CHANGES.AMGEN INC - DMC COMPLETED FIRST PLANNED INTERIM ANALYSIS, WHICH INCLUDED CONSIDERATION OF PRE-SPECIFIED CRITERIA FOR FUTILITY.  Full Article

Cytokinetics Reports Qtrly Loss Per Share Of $0.48
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Cytokinetics Inc ::CYTOKINETICS REPORTS FOURTH QUARTER 2018 FINANCIAL RESULTS.CYTOKINETICS INC QTRLY LOSS PER SHARE $0.48.CYTOKINETICS INC - ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $28 TO $32 MILLION FOR 2019.CYTOKINETICS INC - INTERIM ANALYSIS FOR GALACTIC-HF ON TRACK FOR 1H 2019.  Full Article

Cytokinetics Announces Receipt Of FDA Feedback Regarding Reldesemtiv In Patients With SMA
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Cytokinetics Inc ::CYTOKINETICS ANNOUNCES RECEIPT OF FDA FEEDBACK REGARDING RELDESEMTIV IN PATIENTS WITH SMA.CYTOKINETICS INC - PREPARING TO CONDUCT AN ADDITIONAL PHASE 1 STUDY OF RELDESEMTIV IN VOLUNTEERS; EXPECTED TO BEGIN IN Q1.CYTOKINETICS - RECEIVED FEEDBACK FROM FDA THAT SIX MINUTE WALK TEST IS ACCEPTABLE PRIMARY EFFICACY ENDPOINT FOR POTENTIAL REGISTRATION PROGRAM FOR RELDESEMTIV.  Full Article

Elbit Imaging Announces Gamida Cell Appointed New Chairman
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Elbit Imaging Ltd ::ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL HAS APPOINTED A NEW CHAIRMAN OF THE BOARD.ELBIT IMAGING LTD - ROBERT BLUM CURRENTLY ALSO SERVES AS PRESIDENT AND CEO OF CYTOKINETICS.  Full Article

Cytokinetics And Cure SMA Renew And Expand Partnership To Advance Education And Awareness Of SMA
Thursday, 17 May 2018 

May 17 (Reuters) - Cytokinetics Inc ::CYTOKINETICS AND CURE SMA RENEW AND EXPAND PARTNERSHIP TO ADVANCE EDUCATION AND AWARENESS OF SMA.CYTOKINETICS INC - URE SMA, CO ANNOUNCED EXPANDED PARTNERSHIP TO INCREASE EDUCATION, AWARENESS AND FUNDRAISING FOR SPINAL MUSCULAR ATROPHY.  Full Article

Cytokinetics Qtrly Net Loss Per Share $0.75
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Cytokinetics Inc ::CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​.‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​.QTRLY NET LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Cytokinetics Announces Progress Against Vision 2020
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Cytokinetics Inc ::CYTOKINETICS ANNOUNCES PROGRESS AGAINST VISION 2020.CYTOKINETICS INC - ‍RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018​.CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018.CYTOKINETICS INC - ‍ENROLLMENT OF PATIENTS IN GALACTIC-HF IS ON TRACK IN 2018​.  Full Article

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article